Table 2 Patient characteristics at BC diagnosis and at follow-up
From: Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden
BC only | BC and TC | p-value | |||
|---|---|---|---|---|---|
Mean / No of cases | SD / % | Mean / No of cases | SD / % | ||
No. of patients | 15 | 19 | |||
Age at follow-up | 67.3 | 9.2 | 62.3 | 10.5 | 0.16 |
BC clinical characteristics | |||||
Age at BC diagnosis | 47.7 | 10.2 | 54.4 | 11.2 | 0.079 |
BC grade | 0.363 | ||||
1 | 3 | 37.5% | 3 | 20% | 1 |
2 | 1 | 12.5% | 6 | 40% | 0.104 |
3 | 4 | 50% | 6 | 40% | 1 |
BC T stage | 0.393 | ||||
1 | 4 | 36.4% | 7 | 58.3% | 0.715 |
2 | 6 | 54.5% | 5 | 41.7% | 0.475 |
4 | 1 | 9.1% | 0 | 0% | 0.441 |
Lymph node metastasis | 5 | 33.3% | 8 | 42.1% | 0.728 |
Vascular invasion | 2 | 22.2% | 2 | 15.4% | 1 |
HER2-positivity | 6 | 40% | 4 | 21% | 0.276 |
ER-positivity | 11 | 73% | 10 | 52% | 0.296 |
PR-positivity | 8 | 53% | 8 | 42% | 0.730 |
Invasive ductal carcinoma | 13 | 86.7% | 16 | 84.2% | 1 |
Distant metastasis | 3 | 20% | 2 | 10.5% | 0.634 |
BC radiation therapy | 14 | 93.2% | 17 | 89.5% | 1 |
BC chemotherapy | 10 | 66.7% | 9 | 60% | 1 |
BC hormone therapy | 11 | 73.3% | 10 | 62.5% | 0.704 |
BC targeted therapy | 1 | 6.7% | 2 | 12.5% | 1 |
BC relapse | 4 | 26.7% | 3 | 15.8% | 0.672 |
TC clinical characteristics | |||||
Age at TC diagnosis | – | – | 53.5 | 15 | – |
Papillary histology | – | – | 18 | 94.% | – |
Follicular histology | – | – | 1 | 5.3% | – |
Lymph node metastasis | – | – | 4 | 21% | – |